4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate puritate media >99.0% (HPLC)

Description:

Nomen chemicum: 4-Amino-3-Chlorophenol

CAS: 17609-80-2

Puritas: >99.0% (HPLC)

Aspectus: Brown solidus pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4

Chemical Properties:

Nomen chemicum	4-Amino-3-Chlorophenol
Synonyma	3-Chloro-4-Aminophenol;Lenvaint-G
CAS Number	17609-80-2
CATTUS Number	RF-PI1968
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C6H6ClNO
M. Pondus	143.57
Density	1.406±0.060 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Firmus Pulvis Brown
1 H NMR Spectrum	Congruunt cum Structure
Lepidium sativum-HPLC	Retentio temporis similis vexillum
Puritas / Analysis Methodus	>99.0% (HPLC)
Liquescens punctum	138.0~141.0℃
Damnum in Siccatio	<1.00%
Residere in Ignition	<0.30%
Totalis immunditias	<1.00%
Test Standard	Enterprise Standard
Consuetudinem	Medium de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

4-Amino-3-Chlorophenol (CAS: 17609-80-2) est medium pharmaceuticum magni momenti, quod late in consilio et synthesi adhibetur morborum anti-tumoris, cardiovascularium, morborum neurologicorum medicamentorum.4-Amino-3-Chlorophenolum medium magni momenti est in apparando Mesylate Lenvatinib (CAS: 857890-39-2).Eisai Inc., lenvatinib mesylata enucleata est factor incrementi endothelialis vascularis receptoris (VEGF) inhibitoris qui habet actionem contra VEGF subtyporum 1, 2, et 3, et ab FDA in 2015 probatus est ad curationem cancri thyroideae differentiatae, quae est vel localiter. recurrentes, metastaticae, progressivae vel non respondenti curationi radioactivae iodi.Mense Maio 2016, FDA medicamentum cum everolimo coniunctionis therapiae approbavit ad tractationem carcinomatis renalis promoventis.Quia VEGF (ac receptores fibroblast incrementi factor, ut FGFRs noti) partes agere putantur in viis cardiovascularibus significationis, VEGF2R et FGFR inhibitionis putantur mechanismi post latus primum effectum mesylati lenvatinib, quod est hypertension.